1. Signaling Pathways
  2. Stem Cell/Wnt
  3. Wnt

Wnt

The Wnt signaling pathways are a group of signal transduction pathways made of proteins that pass signals from outside of a cell through cell surface receptors to the inside of the cell. Three Wnt signaling pathways have been characterized: the canonical Wnt pathway, the noncanonical planar cell polarity pathway, and the noncanonical Wnt/calcium pathway. All three Wnt signaling pathways are activated by the binding of a Wnt-protein ligand to a Frizzled family receptor, which passes the biological signal to the protein Dishevelled inside the cell. The canonical Wnt pathway leads to regulation of gene transcription, the noncanonical planar cell polarity pathway regulates the cytoskeleton that is responsible for the shape of the cell, and the noncanonical Wnt/calcium pathway regulates calcium inside the cell. The clinical importance of Wnt signaling pathway has been demonstrated by mutations that lead to a variety of diseases, including breast and prostate cancer, glioblastoma, type II diabetes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-122352
    OSU-03013
    Inhibitor
    OSU-03013 is a Celecoxib (HY-14398) analog. OSU-03013 can promote apoptosis, up-regulate E-cadherin, and down-regulate β-catenin, c-myc, Wnt1, and N-cadherin. OSU-03013 reduces cell migration and invasion. OSU-03013 regulates both Wnt and mTOR expression to inhibit colon cancer (CC) cell proliferation. OSU-03013 can be used for CC cancer research.
    OSU-03013
  • HY-N0889R
    Ginkgetin (Standard)
    Inhibitor
    Ginkgetin (Standard) is the analytical standard of Ginkgetin. This product is intended for research and analytical applications. Ginkgetin, a biflavone, is isolated from Ginkgo biloba leaves. Ginkgetin exhibit anti-tumor, anti-inflammatory, neuroprotective, anti-fungal activities. Ginkgetin is also a potent inhibitor of Wnt signaling, with an IC50 of 5.92 μΜ.
    Ginkgetin (Standard)
  • HY-181560
    SLD1121
    Agonist
    SLD1121 is an agonist of the Wnt/β-catenin signaling pathway that enhances Wnt signaling by targeting LRP6 (Kd: 4.52-7.49 nM). SLD1121 interacts with the intracellular domain of LRP6, stabilizes LRP6, promotes its nuclear translocation, and facilitates its binding to β-catenin, TCF4 or LEF1 in the nucleus, thereby inducing the expression of Wnt-regulated genes and stem cell-related genes. SLD1121 induces the transition of hair follicles from telogen to anagen in the mouse hair growth cycle and promotes hair growth in mice. SLD1121 is applicable to hair loss-related research.
    SLD1121
  • HY-P10392
    aStAx-35R
    Inhibitor
    aStAx-35R, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells.
    aStAx-35R
  • HY-P6441
    KP-6
    Inhibitor
    KP-6, a polypeptide, is a Wnt/β-catenin signal inhibitor. KP-6 inhibits TGF-β and blocks rush fibrosis signal path crucial in vivo. KP-6 suppresses Renal tissues damage and renal fibrosis, and reverse the course of disease of chronic kidney disease (CKD).
    KP-6
  • HY-108516
    TC-E 5001
    Inhibitor
    TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with Kds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC50s of 0.709 μM and 0.215 μM, respectively.
    TC-E 5001
  • HY-N0400R
    Wogonin (Standard)
    Inhibitor
    Wogonin (Standard) is the analytical standard of Wogonin. This product is intended for research and analytical applications. Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.
    Wogonin (Standard)
  • HY-N1411R
    Platycodin D (Standard)
    Platycodin D (Standard) is the analytical standard of Platycodin D. This product is intended for research and analytical applications. Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D.
    Platycodin D (Standard)
  • HY-P11867
    UM206_L
    Activator
    UM206_L is a linear Wnt fragment peptide derived from conserved Wnt3a/Wnt5a sequences, inactive in soluble form but capable of activating canonical Wnt/β-catenin signaling when conjugated to magnetic nanoparticles and exposed to a high-gradient, time-varying magnetic field or immobilized on glass surfaces.
    UM206_L
  • HY-173489
    Wnt/β-catenin-IN-5
    Inhibitor
    Wnt/β-catenin-IN-5 (compound 19T) is a Wnt/β-catenin signaling pathway inhibitor. Wnt/β-catenin-IN-5 inhibits HCT 116, SW480, and A549 cells activity with IC50s of 3.05, 3.27 and 34.91 μM, respectively.
    Wnt/β-catenin-IN-5
  • HY-181541
    HIT211504993
    Inhibitor
    HIT211504993 is a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 0.070 μM. HIT211504993 suppresses cancer cell proliferation, cause G1 phase cell cycle arrest and induces apoptosis. HIT211504993 inhibits Myc-driven tumorigenesis via nucleocytoplasmic acetylation, p53 modulation, and Wnt/β-catenin signaling modulation. HIT211504993 inhibits tumor growth in a colon cancer xenograft mouse model. HIT211504993 can be used for the research of colon cancer.
    HIT211504993
  • HY-131710
    PDE5-IN-3
    Inhibitor
    PDE5-IN-3 (compound 11j) is a potent PDE5 inhibitor with an IC50 of 1.57 nM. PDE5-IN-3 shows moderate EGFR inhibition with IC50 of 5.827 µM. PDE5-IN-3 significantly inhibits the Wnt/β-catenin pathway (IC50=1286.96 ng/mL). PDE5-IN-3 induces the intrinsic apoptotic mitochondrial pathway in HepG2 cells. PDE5-IN-3 has strong antitumor activity.
    PDE5-IN-3
  • HY-168209
    LBM22
    Inhibitor
    LBM22 is a CDC2-like kinase 2 (CLK2) inhibitor with the IC50 of 3.9 nM. LBM22 has antiproliferative activity and inhibits serine/arginine-rich (SR) protein phosphorylation. LBM22 down-regulates the expression of Wnt-related proteins and anti-apoptotic proteins and can be used for study of non-small cell lung cancer.
    LBM22
  • HY-12570
    CK2-IN-9
    Inhibitor
    CK2-IN-9 is a potent and selective inhibitor of CK2 kinase with an IC50 of 3 nM. CK2-IN-9 reduces Wnt reporter activity with an IC50 of 75 nM. CK2-IN-9 has low exposure (AUC=0.36 μM/h) and high clearance (CL=65 mL/min/kg) properties in rat.
    CK2-IN-9
  • HY-P992264
    Anti-LRP6 Antibody
    Anti-LRP6 Antibody is a monoclonal antibody that targets LRP6. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LRP6 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
    Anti-LRP6 Antibody
  • HY-14930S
    Mirodenafil-d7
    Activator
    Mirodenafil-d7 (SK3530-d7) is the deuterium labeled Mirodenafil (HY-14930). Mirodenafil (SK3530) is an orally active, potent, reversible, and selective?phosphodiesterase?5 (PDE5)?inhibitor. Mirodenafil is a?glucocorticoid receptor?(GR)?modulator Mirodenafil activates the?Wnt/β-catenin?signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).
    Mirodenafil-d<sub>7</sub>
  • HY-114178
    CDK8-IN-2
    CDK8-IN-2 is an orally active CDK8 inhibitor of an IC50 values of 0.010 μM. CDK8-IN-2 shows a CDK19 IC50 value of 0.026 μM. CDK8-IN-2 inhibits phospho-STAT1, a pharmacodynamic biomarker of CDK8. CDK8-IN-2 inhibits WNT pathway activity. CDK8-IN-2 can be used for the research of colorectal carcinoma.
    CDK8-IN-2
  • HY-P992300
    Anti-RSPO2 Antibody
    Anti-RSPO2 Antibody is a monoclonal antibody that targets RSPO2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-RSPO2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-RSPO2 Antibody
  • HY-N7171
    4,4'-Di-O-methylellagic acid
    Modulator
    4,4'-Di-O-methylellagic acid (4,4'-DiOMEA; Nasutin C) can be isolated from the Australian termites. 4,4'-Di-O-methylellagic acid is blue-fluorescent under ultra-violet light. 4,4'-Di-O-methylellagic acid inhibits colon cancer cell proliferation via the wnt signal pathway.
    4,4'-Di-O-methylellagic acid
  • HY-181439
    SNX3-IN-1
    Inhibitor
    SNX3-IN-1 is a sorting nexin 3 (SNX3) inhibitor. SNX3-IN-1 reduces SNX3 protein expression and inhibits SNX3-mediated activation of the Wnt/β-catenin signaling pathway. SNX3-IN-1 inhibits the proliferation and migration of pulmonary fibrosis-related cells, and decreases the expression of fibrosis markers α-SMA and COL-1. SNX3-IN-1 can be used in research related to pulmonary fibrosis.
    SNX3-IN-1
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.